Previous Close | 131.15 |
1-Year Change | 40.33% |
6-Months Change | 52.2% |
3-Months Change | 41.86% |
Moving Avg (50d) | 98.89 |
Moving Avg (200d) | 88.65 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 6.21B |
Beta (3-Years) | 0.96 |
Revenue Growth (ttm) | 770.57% |
Net Profit Margin (ttm) | -90.33% |
Return On Assets (ttm) | -33.59% |
EPS (ttm) | -4.55 |
PE Ratio (ttm) | -28.82 |
Dividend Yield | % |
Asset Description: | Axsome Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2025-01-15 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
128.527 | 124.592 | 121.969 | 118.035 | 111.477 | 104.92 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |